Thrombin
6 drugs Cardiovascular
6
approved indications
6
Approved Drugs
6
Companies
9
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (9 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
HETERO LABS LTD III 1 drug
GLAND 1 drug
Fresenius Kabi 1 drug
By Therapeutic Area
Cardiovascular 3 drugs
Other 3 drugs
Drugs by Company PRO
HETERO LABS LTD III 1 drug
GLAND 1 drug
Fresenius Kabi 1 drug
Novartis 1 drug
MAIA PHARMS INC 1 drug
Boehringer Ingelheim 1 drug
By Therapeutic Area
Cardiovascular 3 drugs
DABIGATRAN ETEXILATE MESYLATE, ARGATROBAN, PRADAXA
Other 3 drugs
BIVALIRUDIN, ANGIOMAX, ANGIOMAX RTU
Indications Treated
StrokeSystemic EmbolismAtrial FibrillationDeep Vein ThrombosisPulmonary EmbolismVenous ThromboembolismThrombosisHeparin-Induced ThrombocytopeniaHeparin-Induced Thrombocytopenia and Thrombosis Syndrome
All Drugs Targeting Thrombin
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| DABIGATRAN ETEXILATE MESYLATE Top | HETERO LABS LTD III | 2020 | 6 | Cardiovascular |
| ARGATROBAN | GLAND | 2000 | 2 | Cardiovascular |
| BIVALIRUDIN | Fresenius Kabi | 2015 | 2 | |
| ANGIOMAX | Novartis | 2000 | 2 | |
| ANGIOMAX RTU | MAIA PHARMS INC | 2019 | 2 | |
| PRADAXA | Boehringer Ingelheim | 2010 | 1 | Cardiovascular |